Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -105K | 0 | 0 | 0 | 0 |
| Operating Income | -43M | -28M | -23M | -33M | -39M |
| EBITDA | -43M | -27M | -23M | -32M | -38M |
| Net Income | -15M | -62M | -27M | -41M | -43M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$13.49
+3.37% today
1Y Change
+235.48%
Window
Jun 27, 2025 → Jun 25, 2026
Coverage: 249 bars · Jun 27, 2025 → Jun 25, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Corvus Pharmaceuticals, Inc. (CRVS) is a Healthcare stock with a market cap of $1.32B. The stock last traded around $13.49 and up 235.5% across the available one-year price window (Jun 27, 2025 → Jun 25, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +81.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +81.4%, free cash flow -29.7% with operating margin 0.0% and ROIC -69.1%. Stock Foundry combines CRVS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CRVS
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CRVS Max Drawdown
-56.43%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CRVS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$43.2M
-4.7% YoY
Free Cash Flow
-$36.7M
-34.5% YoY
Revenue Growth
+0.0%
EPS Growth
+81.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -105K | 0 | 0 | 0 | 0 |
| Operating Income | -43M | -28M | -23M | -33M | -39M |
| EBITDA | -43M | -27M | -23M | -32M | -38M |
| Net Income | -15M | -62M | -27M | -41M | -43M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 9M | 13M | 13M | 63M |
| Total Assets | 71M | 69M | 46M | 68M | 109M |
| Total Liabilities | 10M | 36M | 7M | 12M | 12M |
| Shareholder Equity | 61M | 33M | 39M | 56M | 97M |
| Total Debt | 937K | 1M | 1M | 3M | 4M |
| Net Debt | -4M | -8M | -11M | -11M | -60M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
37M
-35.9% YoY
Capital Expenditures
5K
+98.1% YoY
Free Cash Flow
37M
-34.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-23.3%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.